Peptides vs HRT for menopause: what is the difference?

Menopausal hormone therapy and “peptides” get compared constantly in midlife wellness circles, but they are not two flavors of the same treatment. They are different categories with very different track records for menopause. Hormone therapy, usually shortened to HRT, is a long-established prescription medicine that the major medical societies rank as the most effective option for the classic symptoms of the menopausal transition. “Peptides” is a marketing umbrella over a grab-bag of unrelated compounds: a copper skincare ingredient, growth-hormone-releasing peptides, a sleep peptide, a metabolic peptide, and an injectable approved for a narrow sexual-desire indication. Most of them have little or no evidence in menopause. This page lays the two side by side from the menopause guidelines and the FDA drug labels, then explains how a licensed provider actually weighs them. If weight change is your main concern, our companion guide to GLP-1 medication for menopause weight gain goes deeper on that specific question. And if you are already on hormone therapy and wondering whether a peptide can be safely added on top, can you take peptides with HRT is the companion piece on that question.

What is the difference between peptides and HRT for menopause?

The short answer is that HRT is an approved, evidence-backed menopause treatment and peptides, as a group, are not. HRT is a defined class of prescription medicine with menopausal indications approved by the FDA and decades of trial data behind it. “Peptides” is a loose label covering products that range from a cosmetic skincare ingredient to gray-market research chemicals, almost none of which has been studied in menopause at all. The table below maps the two across the dimensions that actually decide a good choice, and each row is expanded and sourced in the sections that follow.

What is menopausal hormone therapy, and what is it approved to treat?

Menopausal hormone therapy is estrogen, taken on its own or, for women who still have a uterus, combined with a progestogen, and it is an FDA-approved treatment for specific menopausal problems. A representative estradiol label lists among its indications the “Treatment of moderate to severe vasomotor symptoms associated with the menopause,” the “Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause,” and the “Prevention of osteoporosis” (Estradiol tablet label, DailyMed). Those are the hot flashes, night sweats, vaginal dryness, and bone loss that define the menopausal transition for many women.

The guidelines are unusually direct about how well it works. The Menopause Society (formerly the North American Menopause Society) states in its 2022 position statement that “Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture” (The 2022 Hormone Therapy Position Statement, Menopause 2022;29(7):767-794). ACOG reaches the same conclusion, describing systemic estrogen therapy as the most effective treatment for menopause-related vasomotor symptoms; notably, ACOG’s guidance also holds that the evidence does not support testosterone, compounded bioidentical hormones, phytoestrogens, or herbal supplements for those symptoms (ACOG clinical guidance on menopausal symptoms, via AAFP). That last point matters here: the same bodies that endorse HRT specifically decline to endorse the unproven alternatives it is often compared against.

HRT is not risk-free, and honest framing requires saying so. The estradiol label carries boxed warnings, beginning with the line “ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER”, which is exactly why a progestogen is added for women who still have a uterus, along with warnings about cardiovascular events, stroke, blood clots, and probable dementia in older women (Estradiol label, DailyMed). The Menopause Society frames the trade-off by timing: “For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss” (The 2022 Hormone Therapy Position Statement). In other words, HRT has real benefits and real risks that a provider weighs against your individual history, which is a very different situation from a therapy with no menopause evidence at all.

What are “peptides” in the menopause conversation, and is any of them approved for menopause?

None of the peptides marketed to women in midlife is approved by the FDA as a menopause treatment, and they are not even one kind of thing. The label gets applied to several unrelated compounds, so it helps to take them one at a time.

GHK-Cu (the copper peptide) is a naturally occurring copper-binding tripeptide found in human plasma, studied for roles in collagen synthesis and skin remodeling and familiar from over-the-counter skincare (Pickart & Margolina, Int J Mol Sci 2018). Most women meet it in topical skincare. It is a skincare ingredient, not a therapy for hot flashes, bone loss, or any core menopausal symptom. Hair thinning sits in a similar gap: a 2022 review in Climacteric notes that HRT is not indicated for skin and hair symptoms alone (Zouboulis et al., 2022), and the prescription option women ask about most, low-dose oral minoxidil, is covered in our guide to oral minoxidil for women.

Growth-hormone-releasing peptides (such as sermorelin, covered in sermorelin for women) and metabolic or sleep peptides like MOTS-C and DSIP are marketed to women for body composition, energy, or sleep. None is approved by the FDA for menopause, and the menopause-specific evidence for them is essentially absent; what research exists is largely in cell or animal models rather than in menopausal women.

Bremelanotide (PT-141), sold as Vyleesi, is the one genuinely approved product in this conversation, and its approval is narrow. Vyleesi is FDA-approved, but only for a specific group: the label indicates it “for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD),” and states plainly that it is “not indicated for the treatment of HSDD in postmenopausal women or in men” (Vyleesi label, DailyMed). Its label also concedes that “The mechanism by which VYLEESI improves HSDD in women is unknown.” So even the approved product here is, by its own labeling, not intended for the menopausal women this page is about; we cover its actual use in PT-141 for women.

How does the evidence compare?

The evidence gap is the heart of the comparison: HRT rests on decades of large clinical trials and current guideline endorsements, while the peptide side ranges from thin to nonexistent for menopause specifically. For HRT, both the Menopause Society and ACOG converge on it being the most effective treatment for vasomotor and genitourinary symptoms, which is about as strong as menopause evidence gets (Menopause Society 2022; ACOG via AAFP). For the peptides, GHK-Cu’s evidence is about skin appearance rather than menopause, and the research peptides are studied mostly in laboratory and animal models with little human data and none in menopausal populations.

GLP-1 medications deserve a separate note because they are often lumped in with “peptides” but sit in a different category. Semaglutide and tirzepatide are a distinct, FDA-approved class of prescription medicine for chronic weight management (sold as the branded products Wegovy and Zepbound), not gray-market research chemicals, and many women use them in midlife. Even there, though, dedicated menopause evidence is still limited: a 2026 review in Cureus concluded that there are no long-term studies of these medications specifically in menopause, that most trials ran only three to six months, and that menopausal women remain underrepresented in clinical research, with much of the data coming from post-hoc analyses of general obesity trials rather than menopause-designed studies (Graczyk & Bisschops, Cureus 2026). The honest read across the board is that HRT is proven for menopausal symptoms, and the peptides, GLP-1s included, are not established menopause treatments.

What are women saying about peptides online?

Online, the peptide side of this comparison is driven by enthusiasm and self-experiment rather than by menopause data. In a July 2026 sample of 19 posts on X about MOTS-c, users mostly described it as an energy and mitochondrial peptide and swapped notes on stacking it with SS-31, NAD+, and other compounds, while others dismissed the trend as hype. In a July 2026 sample of 9 X posts about DSIP, women trying it for midlife night waking described early help that faded, with one reporting grogginess later and another commenter calling it something “most people get nothing from.” Those are self-reports, not trials, and none of them measured hot flashes, vaginal symptoms, or bone, the outcomes where HRT has guideline-level evidence. Our guide to peptides for sleep during menopause covers the DSIP reports in more detail.

Status: MOTS-C: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. DSIP: Not FDA-approved for any use. What these status terms mean.

Which is right for you?

The right choice is a clinical decision, and for the menopausal symptoms this page is about, the option with real evidence and approval behind it is hormone therapy, but whether it fits you depends on your history, your symptoms, and your preferences. A licensed provider reviews your symptom pattern, your personal and family history (including any history of breast cancer, blood clots, or cardiovascular disease), and how far you are past your final period, then talks through HRT, non-hormonal prescription options, and lifestyle measures. Peptides are not a substitute for that evaluation, and no responsible provider commits to a specific prescription before seeing you. A prescription is never promised in advance. If you want to keep reading first, our guide to getting menopause care as a woman over 40 walks through what a first visit actually covers.

Sources

Every clinical figure on this page traces to a menopause guideline, an FDA drug label, or the peer-reviewed literature, listed here so you can verify each claim directly.

• The 2022 Hormone Therapy Position Statement of The North American Menopause Society, Menopause 2022;29(7):767-794 (PubMed), the statements that hormone therapy is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and prevents bone loss/fracture, and that the benefit-risk ratio is favorable for women under 60 or within 10 years of menopause onset.
• The 2022 Hormone Therapy Position Statement (full text, Menopause), the full position statement behind those conclusions.
• Estradiol tablet Prescribing Information (DailyMed), the menopausal indications approved by the FDA (moderate-to-severe vasomotor symptoms, vulvar and vaginal atrophy, prevention of osteoporosis) and the boxed warnings, including the endometrial-cancer warning.
• ACOG clinical guidance on management of menopausal symptoms (summary via AAFP), ACOG’s position that systemic estrogen therapy is the most effective treatment for menopause-related vasomotor symptoms and that the evidence does not support testosterone, compounded bioidentical hormones, phytoestrogens, or herbal supplements for those symptoms.
• Vyleesi (bremelanotide) Prescribing Information (DailyMed), the indication limited to premenopausal women with acquired, generalized HSDD, the limitation of use excluding postmenopausal women and men, and the statement that its mechanism in HSDD is unknown.
• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide, International Journal of Molecular Sciences 2018 (PMC), GHK-Cu as a naturally occurring copper-binding tripeptide studied for collagen synthesis and skin remodeling (a cosmetic/topical context).
• Graczyk NA, Bisschops J. GLP-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review, Cureus 2026 (PMC), the limited, short-duration, and post-hoc nature of GLP-1 evidence specific to menopausal women.
• Zouboulis CC et al. Skin, hair and beyond: the impact of menopause, Climacteric 2022 (PubMed), the statement that HRT is not indicated for skin and hair symptoms alone.

Educational information only, not medical advice. Clinical statements are sourced to the FDA drug labels, the Menopause Society and ACOG guidance, and the peer-reviewed literature linked above. Community summaries describe self-reported posts, not evidence of effect. Last reviewed October 12, 2026.